Research Article| Volume 17, ISSUE 3, P379-389, May 1995

Download started.


Effect of low-dose simvastatin on cholesterol levels, oxidative susceptibility, and antioxidant levels of low-density lipoproteins in patients with hypercholesterolemia: a pilot study

      This paper is only available as a PDF. To read, Please Download here.


      In this pilot study, 12 patients (6 men, 6 postmenopausal women) with hypercholesterolemia were treated with low-dose (5 mg/d) simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, for 4 weeks. Low-density lipoprotein (LDL) samples were isolated at the beginning (week 0) and at the end (week 4) of the treatment regimen. Simvastatin caused significant decreases of total cholesterol (−18.1%), LDL cholesterol (−27.6%), and apolipoprotein B (−21.8%), and significantly reduced total cholesterol, free cholesterol, cholesterol esters, phospholipids, and protein in LDL without significantly changing the component ratios and fatty acid levels of LDL. However, simvastatin therapy had no major effects on either antioxidant levels in LDL or the oxidative susceptibility of LDL. We conclude that low-dose simvastatin significantly reduces LDL cholesterol levels without increasing the oxidative susceptibility of LDL or decreasing the antioxidant levels of LDL, and thus may reduce the risk of coronary artery disease.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Steinberg D
        • Parthasarathy S
        • Carew TE
        • et al.
        Beyond cholesterol. Modifications of low-density lipoprotein cholesterol that increase its atherogenicity.
        NEJM. 1989; 320: 915-924
        • Witztum JL
        • Steinberg D
        Role of oxidized low density lipoprotein in athergenesis.
        J Clin Invest. 1991; 88: 1785-1792
        • Aviram M
        • Dankner G
        • Cogan U
        • et al.
        Lovastatin inhibits low-density lipoprotein oxidation and its fluidity and uptake by macrophages: In vitro and in vivo studies.
        Metabolism. 1992; 41: 229-235
        • Giroux LM
        • Davignon J
        • Naruszewicz M
        Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages.
        Biochim Biophys Acta. 1993; 1165: 335-338
        • Esterbauer H
        • Striegl G
        • Puhl H
        • Waeg G
        The role of vitamin E and carotenoids in preventing oxidation of low density lipoproteins.
        Ann New York Acad Sci. 1989; 570: 254-267
        • Stocker R
        • Bowry VW
        • Frei B
        Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does α-tocopherol.
        Proc Natl Acad Sci USA. 1991; 88: 1646-1650
        • Walker JF
        • Shapiro DR
        Hydroxymethyl-glutaryl coenzyme A reductase inhibitors as monotherapy in the treatment of hypercholesterolemia.
        Am J Cardiol. 1990; 65: 19F-22F
        • The European Study Group
        Efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia (multicountry comparative study).
        Am J Cardiol. 1992; 70: 1281-1286
        • Jones PJH
        • Schoeller DA
        Evidence of diurnal periodicity in human cholesterol synthesis.
        J Lipid Res. 1990; 31: 667-673
        • Havel RL
        • Eder HA
        • Bragon JH
        The distribution and chemical composition of ultracentrifugally separated lipoprotein in human serum.
        J Clin Invest. 1955; 34: 1345-1353
        • Tsai MY
        • Yuan J
        • Hunninghake DB
        Effect of gemfibrozil on composition of lipoproteins and distribution of LDL subspecies.
        Atherosclerosis. 1992; 95: 35-42
        • Warnick GR
        • Benderson J
        • Albers JJ
        Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density lipoprotein cholesterol.
        Clin Chem. 1982; 28: 1379-1388
        • Yoshida H
        • Ayaori M
        • Suzukawa M
        • et al.
        Effects of Ca-antagonists on oxidative susceptibility of low density lipoprotein (LDL).
        Hypertens Res Clin Exp. 1995; 18: 47-53
        • Lowry OH
        • Rosebrough NH
        • Farr AL
        • Randall RJ
        Protein measurement with the folin phenol reagent.
        J Biol Chem. 1951; 193: 265-275
        • Lang JK
        • Gohil K
        • Packer L
        Simultaneous determination of tocopherol, ubiquinols and ubiquinones in blood, plasma, tissue homogenates and subcellular fraction.
        Anal Biochem. 1986; 157: 106-116
        • Croft KD
        • Dimmitt SB
        • Moulton C
        • Beilin LJ
        Low density lipoprotein composition and oxidizability in coronary disease—apparent favorable effect of beta-blockers.
        Atherosclerosis. 1992; 97: 123-130
        • Folch J
        • Lees M
        • Soloana-Stanley GH
        A simple method for the isolation and purification of total lipids from animal tissues.
        J Biol Chem. 1957; 226: 497-509
        • Ishikawa T
        • Fujiyama T
        • Igarashi O
        • et al.
        Effects of gamma-linolenic acid on plasma lipoproteins and apolipoproteins.
        Atherosclerosis. 1989; 75: 95-104
        • Friedewald WT
        • Levy RI
        • Fredrickson DS
        Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.
        Clin Chem. 1972; 18: 499-502
        • Esterbauer H
        • Striegl G
        • Puhl H
        • Rothender M
        Continuous monitoring of in vitro oxidation of human low density lipoprotein.
        Free Radic Res Commun. 1989; 6: 67-75
        • Suzukawa M
        • Ishikawa T
        • Yoshida H
        • et al.
        Effects of alcohol consumption on antioxidant content and susceptibility of low-density lipoprotein to oxidative modification.
        J Am Coll Nutr. 1994; 13: 237-242
        • Jialal I
        • Grundy SM
        Effect of dietary supplementation with α-tocopherol on the oxidative modification of low-density lipoprotein.
        J Lipid Res. 1992; 33: 899-906
        • Reaven PD
        • Khnouw A
        • Beltz WF
        • et al.
        Effect of dietary antioxidant combination in humans: Protection of LDL by vitamin E but not by β-carotene.
        Arterioscler Thromb. 1993; 13: 590-600
        • Abbey M
        • Nestel PJ
        • Baghurst PA
        Antioxidant vitamins and low-density-lipoprotein oxidation.
        Am J Clin Nutr. 1993; 58: 525-532
        • Willis RA
        • Folkers K
        • Tucker JL
        • et al.
        Lovastatin decreases coenzyme Q levels in rats.
        Proc Natl Acad Sci USA. 1990; 87: 8928-8930
        • Folkers K
        • Langsjoen P
        • Willis R
        • et al.
        Lovastatin decreases coenzyme Q levels in human.
        Proc Natl Acad Sci USA. 1990; 87: 8931-8934
        • Germershausen JI
        • Hunt VM
        • Bostedor RG
        • et al.
        Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo.
        Biochem Biophys Res Commun. 1989; 158: 667-675
        • Stubbs RJ
        • Schwartz MS
        • Gerson RJ
        • et al.
        Comparison of plasma profiles of lovastatin (Mevinolin), simvastatin (Epistatin) and pravastatin (Eptastatin) in the dog.
        Drug Invest. 1990; 2 (Suppl 2): 18-28
        • Berry EM
        • Eisenberg S
        • Maratz D
        • et al.
        Effects of diets rich in monounsaturated fatty acids on plasma lipoproteins—the Jerusalem Nutrition Study: High MUFAs vs high PUFAs.
        Am J Clin Nutr. 1991; 53: 899-907
        • Reaven PD
        • Parthasarathy S
        • Grasses BJ
        • et al.
        Effects of oleate-rich and linoleate-rich diets on the susceptibility of low density lipoprotein to oxidative modification in mildly hypercholesterolemic subjects.
        J Clin Invest. 1993; 91: 668-676
        • Regnstrom J
        • Nilsson J
        • Tornvall P
        • et al.
        Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man.
        Lancet. 1992; 339: 1183-1186
        • De Graaf J
        • Hak-Lemmers HLM
        • Hectors MPC
        • et al.
        Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects.
        Arterioscler Thromb. 1991; 11: 298-306
        • Tribble DL
        • Holl LG
        • Wood PD
        • Krauss RM
        Variations in oxidative susceptibility of differing density and particle size.
        Atherosclerosis. 1992; 93: 189-199
        • Austin MA
        • Breslow JL
        • Hennekens CH
        • et al.
        Low-density lipoprotein subclass patterns and risk of myocardial infarction.
        JAMA. 1988; 260: 1917-1921
        • Campos H
        • Genest Jr, JJ
        • Blijlevens E
        • et al.
        Low density lipoprotein particle size and coronary artery disease.
        Arterioscler Thromb. 1992; 12: 187-195
        • Campos H
        • Blijlevens E
        • McNamara JR
        • et al.
        LDL particle distribution: Results from the Framingham Offspring Study.
        Arterioscler Thromb. 1992; 12: 1410-1419
        • McNamara JR
        • Campos H
        • Ordovas JM
        • et al.
        Effect of gender, age, and lipid status on low density lipoprotein subfraction disributioin. Results from Framingham Offspring Study.
        Arteriosclerosis. 1987; 7: 483-490
        • Swinkels DW
        • Demaker PNM
        • Hendricks JCM
        • Van't Laar A
        Low density lipoprotein subfractions and relationship to other risk factors for coronary artery disease in healthy individuals.
        Arteriosclerosis. 1989; 9: 604-613
        • Fuller JH
        • Shipley MJ
        • Rose G
        • et al.
        Coronary-heart-disease risk and impaired glucose tolerance.
        Lancet. 1980; 1: 1373-1376
        • Ducimetiere P
        • Eschwege E
        • Papoz L
        • et al.
        Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population.
        Diabetologia. 1980; 19: 205-210
        • Sheu WHH
        • Shieh SM
        • Shen DDC
        • et al.
        Effect of pravastatin treatment on glucose, insulin, and lipoprotein metabolism in patients with hypercholesterolemia.
        Am Heart J. 1994; 127: 331-336